BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22535637)

  • 1. Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.
    Vetter D; Cohen-Naftaly M; Villanueva A; Lee YA; Kocabayoglu P; Hannivoort R; Narla G; M Llovet J; Thung SN; Friedman SL
    Hepatology; 2012 Oct; 56(4):1361-70. PubMed ID: 22535637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.
    Yea S; Narla G; Zhao X; Garg R; Tal-Kremer S; Hod E; Villanueva A; Loke J; Tarocchi M; Akita K; Shirasawa S; Sasazuki T; Martignetti JA; Llovet JM; Friedman SL
    Gastroenterology; 2008 May; 134(5):1521-31. PubMed ID: 18471523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.
    Tarocchi M; Hannivoort R; Hoshida Y; Lee UE; Vetter D; Narla G; Villanueva A; Oren M; Llovet JM; Friedman SL
    Hepatology; 2011 Aug; 54(2):522-31. PubMed ID: 21563203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
    Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
    Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.
    Narla G; DiFeo A; Fernandez Y; Dhanasekaran S; Huang F; Sangodkar J; Hod E; Leake D; Friedman SL; Hall SJ; Chinnaiyan AM; Gerald WL; Rubin MA; Martignetti JA
    J Clin Invest; 2008 Aug; 118(8):2711-21. PubMed ID: 18596922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform.
    Liang WC; Wang Y; Xiao LJ; Wang YB; Fu WM; Wang WM; Jiang HQ; Qi W; Wan DC; Zhang JF; Waye MM
    RNA Biol; 2014; 11(7):845-54. PubMed ID: 24921656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma.
    Narla G; Kremer-Tal S; Matsumoto N; Zhao X; Yao S; Kelley K; Tarocchi M; Friedman SL
    Oncogene; 2007 Jun; 26(30):4428-34. PubMed ID: 17297474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer.
    Chen H; Chen L; Sun L; Zhen H; Li X; Zhang Q
    Gastric Cancer; 2011 Oct; 14(4):339-52. PubMed ID: 21538018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.
    Bechmann LP; Gastaldelli A; Vetter D; Patman GL; Pascoe L; Hannivoort RA; Lee UE; Fiel I; Muñoz U; Ciociaro D; Lee YM; Buzzigoli E; Miele L; Hui KY; Bugianesi E; Burt AD; Day CP; Mari A; Agius L; Walker M; Friedman SL; Reeves HL
    Hepatology; 2012 Apr; 55(4):1083-93. PubMed ID: 22095588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.
    Kremer-Tal S; Narla G; Chen Y; Hod E; DiFeo A; Yea S; Lee JS; Schwartz M; Thung SN; Fiel IM; Banck M; Zimran E; Thorgeirsson SS; Mazzaferro V; Bruix J; Martignetti JA; Llovet JM; Friedman SL
    J Hepatol; 2007 Apr; 46(4):645-54. PubMed ID: 17196295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.
    Ghiassi-Nejad Z; Hernandez-Gea V; Woodrell C; Lang UE; Dumic K; Kwong A; Friedman SL
    Hepatology; 2013 Feb; 57(2):786-96. PubMed ID: 22961688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.
    Hatami R; Sieuwerts AM; Izadmehr S; Yao Z; Qiao RF; Papa L; Look MP; Smid M; Ohlssen J; Levine AC; Germain D; Burstein D; Kirschenbaum A; DiFeo A; Foekens JA; Narla G
    Sci Transl Med; 2013 Jan; 5(169):169ra12. PubMed ID: 23345610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of the tumor suppressor Krüppel-like factor 6 (KLF6) by mutation or decreased expression in hepatocellular carcinomas.
    Pan XC; Chen Z; Chen F; Chen XH; Jin HY; Xu XY
    J Zhejiang Univ Sci B; 2006 Oct; 7(10):830-6. PubMed ID: 16972326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination.
    Ahronian LG; Zhu LJ; Chen YW; Chu HC; Klimstra DS; Lewis BC
    Oncogene; 2016 Sep; 35(35):4653-62. PubMed ID: 26876204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.
    Sangodkar J; DiFeo A; Feld L; Bromberg R; Schwartz R; Huang F; Terzo EA; Choudhri A; Narla G
    Lung Cancer; 2009 Dec; 66(3):292-7. PubMed ID: 19328586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kruppel-like factor 6 suppresses growth and invasion of hepatocellular carcinoma cells in vitro and in vivo.
    Wen PH; Wang DY; Zhang JK; Wang ZH; Pan J; Shi XY; Yang H; Zhang SJ; Guo WZ
    Int J Immunopathol Pharmacol; 2016 Dec; 29(4):666-675. PubMed ID: 27510817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of KLF6 and its splice variants in cancer therapy.
    DiFeo A; Martignetti JA; Narla G
    Drug Resist Updat; 2009; 12(1-2):1-7. PubMed ID: 19097929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
    Narla G; DiFeo A; Yao S; Banno A; Hod E; Reeves HL; Qiao RF; Camacho-Vanegas O; Levine A; Kirschenbaum A; Chan AM; Friedman SL; Martignetti JA
    Cancer Res; 2005 Jul; 65(13):5761-8. PubMed ID: 15994951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.
    DiFeo A; Narla G; Hirshfeld J; Camacho-Vanegas O; Narla J; Rose SL; Kalir T; Yao S; Levine A; Birrer MJ; Bonome T; Friedman SL; Buller RE; Martignetti JA
    Clin Cancer Res; 2006 Jun; 12(12):3730-9. PubMed ID: 16778100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.
    Camacho-Vanegas O; Narla G; Teixeira MS; DiFeo A; Misra A; Singh G; Chan AM; Friedman SL; Feuerstein BG; Martignetti JA
    Int J Cancer; 2007 Sep; 121(6):1390-5. PubMed ID: 17514651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.